NEW YORK (GenomeWeb News) – Enzo Biochem today said that it has signed an agreement to market Sequenom's MaterniT21 Plus test service in the northeast US.

The sequencing-based test, which is performed at the Sequenom Center for Molecular Medicine, analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. It is intended for use in pregnant women at increased risk for fetal aneuploidy, can be used as early as 10 weeks' gestation.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.

Sep
17
Sponsored by
SeraCare

Today’s challenging clinical next-generation sequencing applications require a rigorous, comprehensive quality control management program to ensure confidence in results.